BioPharma Dive1d
Sanofi, Teva add to case for new bowel disease drug
Detailed results presented at a medical congress help reinforce analyst expectations the drug, called duvakitug, will be ...
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...
ENDPOINTS NEWS1d
Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion
Sanofi & Teva's IBD drug duvakitug shows promise in Phase 2b with €1B sales potential by 2032, faces competition from Roivant ...
FierceBiotech1d
Sanofi shows how $500M bowel disease bet compares to Merck and Roche's rival assets
Sanofi has shared a deeper dive into its 469 million euro ($491 million) bowel disease bet, publishing phase 2 data that ...
Sanofi and Teva report new outcomes from Phase IIb trial of duvakitug
Sanofi and Teva Pharmaceuticals have reported new outcomes from the randomised Phase IIb RELIEVE UCCD trial of human ...
Teva, Sanofi present new results from RELIEVE UCCD Phase 2b study
Teva Pharmaceuticals (TEVA), and Sanofi (SNY) presented new, detailed results from the RELIEVE UCCD Phase 2b study of duvakitug, a human IgG1-2 ...
Teva share price struggles to recover following $6 billion market loss
The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...
Pharm Exec12d
The Teva Turnaround: Steering a Company Comeback
CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...
Sanofi: ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease
ECCO 2025: new duvakitug data reinforce best-in-class potential in ulcerative colitis and Crohn's disease New detailed data from the RELIEVE UCCD study support overall efficacy and safety of duvakitug ...